Preface xii

Acknowledgements xv

1 Somatostatin: The History of Discovery 1
Malgorzata Trofimiuk‐Müldner and Alicja Hubalewska‐Dydejczyk

2 Physiology of Endogenous Somatostatin Family: Somatostatin Receptor Subtypes, Secretion, Function and Regulation, and Organ Specific Distribution 6
Marily Theodoropoulou

3 Somatostatin Receptors in Malignancies and Other Pathologies 21
Marco Volante, Adele Cassenti, Ida Rapa, Luisella Righi, and Mauro Papotti

4 The Use of Radiolabeled Somatostatin Analogue in Medical Diagnosis: Introduction 31
Alberto Signore

4.1 Somatostatin Receptor Scintigraphy‐SPECT 35
Renata Mikołajczak and Alberto Signore

4.2 Molecular Imaging of Somatostatin Receptor‐Positive Tumors Using PET/CT 55

Richard P. Baum and Harshad R. Kulkarni
4.3 Other Radiopharmaceuticals for Imaging GEP‐NET 75
Klaas Pieter Koopmans, Rudi A. Dierckx, Philip H. Elsinga, Thera P. Links, Ido P. Kema, Helle-Brit Fiebrich, Annemieke M.E. Walekamp, Elisabeth G.E. de Vries, and Adrienne H. Brouwers

4.4 The Place of Somatostatin Receptor Scintigraphy in Clinical Setting: Introduction 86
Alicja Hubalewska‐Dydejczyk

4.4.1 Somatostatin Receptor Scintigraphy in Management of Patients with Neuroendocrine Neoplasms 90
Anna Sowa‐Staszczak, Agnieszka Stefańska, Agata Jabrocka‐Hybel, and Alicja Hubalewska‐Dydejczyk

4.4.2 The Place of Somatostatin Receptor Scintigraphy and Other Functional Imaging Modalities in the Setting of Pheochromocytoma and Paraganglioma 112
Alicja Hubalewska‐Dydejczyk, Henri J.L.M. Timmers, and Malgorzata Trofimiuk‐Müldner

4.4.3 Somatostatin Receptor Scintigraphy in Medullary Thyroid Cancer 127
Anouk N.A. van der Horst‐Schrivers, Adrienne H. Brouwers, and Thera P. Links

4.4.4 Somatostatin Receptor Scintigraphy in Other Tumors Imaging 135
Malgorzata Trofimiuk‐Müldner and Alicja Hubalewska‐Dydejczyk

4.4.5 Somatostatin Receptor Scintigraphy in Inflammation and Infection Imaging 153
Alberto Signore, Kelly Luz Anzola Fuentes, and Marco Chianelli

5 Somatostatin Analogues in Pharmacotherapy: Introduction 164
Wouter W. de Herder

5.1 Somatostatin Analogues in Pharmacotherapy 166
Wouter W. de Herder

5.2 Pituitary Tumor Treatment with Somatostatin Analogues 169
Alicja Hubalewska-Dydejczyk, Aleksandra Gilis-Januszewska, and Malgorzata Trofimiuk-Müldner

5.3 Somatostatin Analogues in Pharmacotherapy of Gastroenteropancreatic Neuroendocrine Tumors 189
Frédérique Maire and Philippe Ruszniewski

5.4 Somatostatin Analogue Use in Other than Endocrine Tumor Indications 198
Aleksandra Gilis‐Januszewska, Malgorzata Trofimiuk‐Müldner, Agata Jabrocka‐Hybel,, and Dorota Pach

6 Peptide Receptor Radionuclide Therapy Using Radiolabeled Somatostatin Analogues: An Introduction 207
John Buscombe

6.1 Somatostatin Analogues and Radionuclides Used in Therapy 214
Esther I. van Vliet, Boen L.R. Kam, Jaap J.M. Teunissen, Marion de Jong, Eric P. Krenning, and Dik J. Kwekkeboom

6.2 PRRT Dosimetry 230
Mark Konijnenberg

6.3 Peptide Receptor Radionuclide Therapy (PRRT): Clinical Application 252
Lisa Bodei, and Giovanni Paganelli

6.4 Duo‐PRRT of Neuroendocrine Tumors Using Concurrent and Sequential Administration of Y‐90‐ and Lu‐177‐Labeled Somatostatin Analogues 264
Richard P. Baum and Harshad R. Kulkarni

6.5 N onsystemic Treatment of Liver Metastases from Neuroendocrine Tumor 273
Daniel Putzer, Gerlig Widmann, Dietmar Waitz, Werner Jaschke, and Irene J. Virgolini

6.6 Peptide Receptor Radionuclide Therapy: Other Indications 282
Agnieszka Stefańska, Alicja Hubalewska‐Dydejczyk, Agata Jabrocka‐Hybel, and Anna Sowa‐Staszczak

7 Somatostatin Analogs: Future Perspectives and Preclinical Studies—Pansomatostatins 291
Aikaterini Tatsi Berthold A. Nock, Theodosia Maina, and Marion de Jong

8 Radiolabeled Somatostatin Receptor Antagonists 305
Melpomeni Fani and Helmut R. Maecke

9 Cortistatins and Dopastatins 321
Manuela Albertelli and Diego Ferone

Index 000